Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$2.88 USD
+0.26 (9.92%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $2.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.88 USD
+0.26 (9.92%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $2.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Zacks News
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
by Zacks Equity Research
Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nuvation Bio Inc. (NUVB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Nuvation Bio Inc. (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
by Zacks Equity Research
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.